Abstract: Nanofiber structures are provided as well as methods of use thereof and methods of making.

Abstract: Processes for preparing neutral liposomes include adding a hydrophobic solution of liposome lipid bilayer precursors and a nucleic acid condenser to an aqueous composition of a nucleic acid condenser and a biologically active ingredient and then, isolating the liposomes. The liposomes are formed from noncationic lipids and encapsulate the biologically active ingredient as a core composition and entrap some of the biologically active ingredient on the exterior surface of the liposome. The liposomes have the nucleic acid condensers and/or cell penetrating peptides attached to the exterior surface of the lipid bilayer. One or more divalent cations are present in the solution with the liposome and remain in solution once the liposomes form.

Abstract: A composition, and method for a targeted drug delivery is disclosed in treating central nervous system injury, including blast hearing loss, traumatic brain injury (TBI) and the like, by administering a subject with nanoparticle-based minocycline formulations. The formulation contains nanoparticles encapsulating minocycline for neuroprotective effect in TBI. Albumin nanoparticle-based minocycline formulations provide enhanced delivery to brain, and reduced toxicity at minimal dosage for treating a subject suffering from central nervous system injury including blast induced traumatic brain injury (bTBI). Nanoparticle administered at minimal dose in rat blast TBI model crossed blood-brain barrier (BBB) and enhanced therapeutic concentration compared to free minocycline. Provided is an effective and safe minocycline delivery in TBI with minimal or no toxicity for neuroprotective therapy.

Abstract: A method for encapsulating active ingredients in liposomes having an active ingredient solution encapsulated with a bilayer composed of two monomolecular layers of a first and a second amphiphilic compound, wherein the method comprises: (a) providing the active ingredient solution; (b) providing an emulsion by emulsifying the active ingredient solution in a first liquid in the presence of the first amphiphilic compound; (c) providing a mixture with a liquid phase with the second amphiphilic compound; (d) contacting the first emulsion with the mixture to form a phase boundary; and (e) centrifuging the first emulsion and the mixture wherein, on passage of the phase boundary, the second amphiphilic compound enriched there is added onto the monomolecular inner layer of the pre-liposomes to form a monomolecular outer layer, in order to create the bilayer.

Abstract: A hybrid scaffold is disclosed which is made of materials that define peripheral layers designed to interface with the tissues in the implant site and one or more intermediate layers. The materials are combined to give the scaffold mechanical properties suitable for withstanding the stresses of the implant site. The materials are fibroin for the peripheral layers and polyurethane combined with fibroin for each intermediate layer.

Abstract: The present invention provides a composition, comprising ferrous amino acid chelate particles sintered from ferrous amino acid chelate, wherein the average particle size of the ferrous amino acid chelate particles ranges from 500 nm to 2600 nm, and the average molecular weight of the particles ranges from 1,500 Dalton to 600,000 Dalton. Besides, the present invention can be used for manufacturing a medicament for treating or ameliorating a pancreas-related disease, wherein the medicament comprises an effective amount of the composition and a pharmaceutically acceptable carrier.

Abstract: A type II crystalline topramezone sodium salt hydrate, a preparation method of the type II crystalline topramezone sodium salt hydrate and the use thereof in herbicidal compositions is provided. An X-ray powder diffraction pattern of the hydrate recorded by Cu-Ka radiation at 25° C. shows at least 3 of the following reflections at 2? values: 2?=9.63±0.2°??(1) 2?=11.00±0.2°??(2) 2?=11.97±0.2°??(3) 2?=13.13±0.2°??(4) 2?=14.36±0.2°??(5) 2?=15.37±0.2°??(6) 2?=17.24±0.2°??(7) 2?=18.01±0.2°??(8) 2?=19.12±0.2°??(9) 2?=19.65±0.2°??(10) 2?=22.03±0.2°??(11) 2?=23.20±0.2°??(12) 2?=25.29±0.2°??(13) 2?=27.29±0.2°??(14) 2?=27.93±0.2°??(15) 2?=28.90±0.2°??(16).

Abstract: The present disclosure relates to a novel spherical agglomeration method for proteins, and protein particles made by the spherical agglomeration method. By using continuous oscillatory baffled crystallizer, the method of the present disclosure is capable of maintain the biologically activities and providing protein particles with an average particle size between 1-500 ?m.

Abstract: A composition of psilocin that is stable including at least one agent or chemical modification that provides enhanced stability. A method making stable psilocin, by providing a formulation of psilocin including at least one agent or chemical modification that provides enhanced stability. A method of treatment of a disease or condition, by administering a composition of psilocin that is stable to an individual and treating the disease or condition.